Q2
JNJ — Q2 2026 Financial Report Analysis
Johnson & Johnson posted its first $25 billion quarter with sales up 6.6%, but a jump in the effective tax rate to 18.0% from 14.7% left net income flat — while TREMFYA's $860M gain covered 94% of STELARA's patent-cliff decline and MedTech growth slowed to 3.6%.